U.S. Pancreatic Cancer Precision Medicine Market Size & Outlook

Name: U.S. Pancreatic Cancer Precision Medicine Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The pancreatic cancer precision medicine market in the United States is expected to reach a projected revenue of US$ 1,062.3 million by 2033. A compound annual growth rate of 18.7% is expected of the United States pancreatic cancer precision medicine market from 2026 to 2033.

Pharmaceuticals
- Oncology Drugs
  - Pancreatic Cancer Precision Medicine Market Outlook

U.S. pancreatic cancer precision medicine therapeutic approach outlook (Revenue, USD million, 2021-2033)
- Targeted Therapy
  - PARP Inhibitors
  - Monoclonal Antibodies
  - Small Molecule Inhibitors - EGFR inhibitors, KRAS inhibitors
- Immunotherapy
  - Immune Checkpoint Inhibitors - PD-1 inhibitors, PD-L1 inhibitors
  - Cancer Vaccines - GVAX, Algenpantucel-L
  - Adoptive T-Cell Therapies - CAR-T therapies
- Chemotherapy-Precision Combinations
- Other Therapeutic Approaches
U.S. pancreatic cancer precision medicine diagnostic technology outlook (Revenue, USD million, 2021-2033)
- Genomic Testing
- Molecular Diagnostics
- Liquid Biopsy
- Biomarker-based Companion Diagnostics
- Others (Immunohistochemistry (IHC), Proteomics, Mass spectrometry)

U.S. Pancreatic Cancer Precision Medicine Market Size & Outlook

Data Tree

Sign up - it's easy, and free!